 Å, b = 14.6602 (9) Å, c = 14.8530 (9) Å, α = 67.205 (4)°, β = 80.388 (5)
INTRODUCTION
A substantial increase in fungal infections has been observed over the past few decades. Invasive and nosocomial fungal infections are primarily caused by Candida and Aspergillus species, where Candida albicans is responsible for the majority of invasive and superficial Candida infections.
The azole antifungal agents constitute a major antifungal class and contain an azole pharmacophoric moiety. In spite of the fact that there is a growing list of new antifungal agents, the treatment of fungal infections remains unsatisfactory in many cases. Furthermore, the use of many antifungal drugs is often complicated by clinical obstacles, including a suboptimal spectrum of activity, hazardous drugdrug interactions, toxicity, and limited bioavailability [1] [2] [3] [4] [5] [6] . Consequently, the search for novel antifungal agents is urgently needed for clinical therapy.
The molecular structure of the anti-Candida oximino ester, namely ({[(1E)-3-(1H-imidazol-1-yl)-1-phenylpropylidene]amino}oxy)(3,4,5-trimethoxyphenyl)methanone (4) has not been previously investigated. Herein, we report the molecular structure as well as the configuration of the imine moiety of the oximino ester 4 using x-ray crystallography as an unambiguous analytical tool.
EXPERIMENTAL General
Melting points were determined on a Gallenkamp melting point apparatus and are uncorrected. NMR spectra were carried out on a Bruker NMR spectrometer operating at 500 
Chemistry

Preparation of 3-(1H-imidazol-1-yl)-1-phenylpropan-1-one (2)
A catalytic amount of concentrated hydrochloric acid (0.1 mL) was added to a mixture of acetophenone (2.4 g, 20 mmol), dimethylamine hydrochloride (2.2 g, 27 mmol) and paraformaldehyde (0.81 g, 9 mmol). The reaction mixture was refluxed in absolute ethanol (5 mL) for two hours. Acetone (20 mL) was added to the cooled reaction mixture in order to precipitate the Mannich base hydrochloride 1. A solution containing compound 1 (3.7 g, 17.4 mmol) and imidazole (2.4 g, 34.8 mmol) in water (10 mL) was refluxed for five hours. Cooling the reaction mixture led to precipitation of the ketone 2 which was filtered off to give 2.7 g (77%) of 2 mp 368-370 K [7] . Ketone 2 was used in the next step without any further purification, and its chemical structure was confirmed via 
Preparation of (1E)-N-hydroxy-3-(1H-imidazol-1-yl)-1-phenylpropan-1-imine (3)
Hydroxylamine hydrochloride (1.39 g, 20 mmol) was added to a solution containing ketone 2 (2.00 g, 10 mmol) and KOH (1.12 g, 20 mmol) in ethanol (10 mL). The reaction was stirred under reflux for 18 h, cooled to ambient temperature, and filtered. After concentrating the filtrate under reduced pressure, the residue was poured onto ice-cold water (15 mL). The precipitated solid was filtered, dried and re-crystallized from ethanol to yield 1.51 g (70 %) of compound 3 as colorless crystals with mp 428-430 K [8] . The assigned chemical structure of oxime 3 was confirmed via 1 H and 13 C NMR and mass spectral data.
Preparation of ({[(1E)-3-(1H-imidazol-1-yl)-1-phenylpropylidene]amino}oxy)(3,4,5-trimethoxyphenyl)methanone (4)
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI.HCl, 1.40 g, 7.3 mmol) was added to a stirred solution containing 3,4,5-trimethoxybenzoic acid (1.49 g, 7 mmol) and 4-dimethylaminopyridine (DMAP, 400 mg) in dichloromethane (75 mL). Thereafter, oxime 3 (1.49 g, 6.9 mmol) was added and the reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was successively washed with water (2 x 20 mL), a 10 % NaHCO 3 solution (2 x 15 mL), and water (2 x 15 mL). The organic phase was separated, dried (Na 2 SO 4 ), and evaporated under vacuum. The residue was re-crystallized (isopropanol) to yield 1.50 g (53 %) of the target oximino ester 4 as colorless crystals with mp 408-410 K [8] . The assigned chemical structure of compound 4 was confirmed via 1 H and 13 C NMR and mass spectral data.
Crystal structure determination
The slow evaporation of the isopropanol solution containing pure oximino ester 4 afforded its colorless block single crystals. A single crystal with dimensions of 0.32 × 0.23 × 0.05 mm was selected for x-ray diffraction analysis. Data were collected on a Bruker APEX-II CCD area diffractometer equipped with graphite monochromatic CuKa radiation (λ = 1.54178 Å) at 296 (2) K.
RESULTS
Synthetic reactions
Oximino ester 4 was obtained as shown in Scheme 1. Briefly, acetophenone was subjected to a Mannich reaction followed by substitution of the resulting Mannich base hydrochloride 1 with imidazole to furnish the pivotal ketone 2. Subsequently, the ketone function in compound 2 was transformed to an oxime via reaction with hydroxylamine hydrochloride in the presence of potassium hydroxide to yield the oxime 3. Esterification of the hydroxyl moiety in compound 3 with 3,4,5-trimethoxybenzoic acid in the presence of the coupling agent EDCI.HCl and DMAP provided the target oximino ester 4. + [8] .
3-(1H-Imidazol-1-yl)-1-phenylpropan-1-one (2)
Crystal structure of the target oximino ester 4
Cell refinement and data reduction were performed using Bruker SAINT [9] . SHELXS-97 [10] was used to solve and refine the structure. The final refinement was performed using the full-matrix least-squares techniques with anisotropic thermal data for non-hydrogen atoms on F2. All hydrogen atoms were placed in calculated positions and constrained to ride on their parent atoms. Multi-scan absorption correction was applied using SADABS software [9] . The crystallographic data and refinement information are summarized in Table 1 , and the selected bond lengths and angles are listed in Table 2 . The labeled displacement ellipsoid plot is shown in Figure 1 , in which the minor disordered component has been omitted for clarity. Figure 2 depicts the packing of the molecules in the crystal structure. Table 2 : Selected geometric parameters, bond length and bond angles (Å, °). 
Atom
DISCUSSION
The chemical structures of the synthesized compounds were confirmed via spectral analysis including 1 H NMR,
13
C NMR, and mass spectral data. The target oximino ester 4 has exhibited potential in vitro anti-Candida activity and has been evaluated using clinical isolates of C. albicans and C. tropicalis. It has a MIC value of 0.3053 µmol/mL against both C. albicans and C. tropicalis and is approximately 5-fold more potent than the gold standard antifungal agent fluconazole (MIC ˃1.6325 µmol/mL) [8] .
The configuration of the anti-Candida oximino ester 4 was confirmed via x-ray crystallography approach as an analytical tool to unequivocally assign its structure. In this manner, the imine group in the target compound 4 was assigned an (E)-configuration.
The crystal structure of 4 contains two molecules in the asymmetric unit. The phenyl ring (C1-C6) forms dihedral angles of 8.76 (3)° and 12.13 (2)° with the benzene ring (C12-C17), in the two molecules. The phenyl ring (C1-C6) also forms dihedral angles of 70.75(1)° and 65.80(2)° with the imidazole ring (N2-C20-C21-N3-C22), in the two molecules. Furthermore, the phenyl ring (C12-C17) forms dihedral angles of 64.63 (1)° and 64.76(2)° with the imidazole ring (N2-C20-C21-N3-C22) in the two molecules. The crystal
